Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.54 |
| ▸ | SIRT6 | Q8N6T7 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4827771 | 0.90 | MAPK14 (0.60) | MAPK14SIRT6 | |
| SCHEMBL4831994 | 0.89 | MAPK14 (0.57) | MAPK14MAPK13 | |
| SCHEMBL4827646 | 0.86 | NPC1 (0.54) | MAPK14NPC1RAB9AMAPTLMNA | |
| SCHEMBL6401762 | 0.82 | SIRT6 (0.54) | SIRT6NPC1RAB9AMAPTLMNA | |
| SCHEMBL27492359 | 0.81 | SIRT6 (0.49) | SIRT6 | |
| SCHEMBL4829619 | 0.80 | MAPK14 (0.51) | MAPK14NPC1RAB9AMAPTLMNA | |
| SCHEMBL4833935 | 0.79 | NPC1 (0.61) | MAPK14NPC1RAB9AMAPTLMNA | |
| SCHEMBL4831590 | 0.79 | MAPK14 (0.63) | MAPK14 | |
| SCHEMBL28676274 | 0.78 | SIRT6 (0.83) | SIRT6NPC1RAB9AMAPTPOLB | |
| SCHEMBL31524049 | 0.78 | MAPK14 (0.65) | MAPK14NPC1RAB9AMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | MAPK14 2834/4885SIRT6 336/4885NPC1 823/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | MAPK14 2834/4885SIRT6 336/4885NPC1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.